Cargando…
2372. Preliminary evidence of durable immune responses induced by self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 in vaccine-naive South African population
BACKGROUND: CORAL-CEPI (NCT05435027) is the first test of samRNA-based SARS-CoV-2 vaccines in the African population, under-represented in SARS-CoV-2 vaccine studies. Antibody transience is an issue with first generation SARS-CoV-2 vaccines. This is a preliminary safety and immunogenicity report, sh...
Autores principales: | Koen, A, Mitha, E, Allagappen, J, Nagare, A, Dhar, M, Marrali, M, Palmer, Christine, Venkatraman, Harshni, Jaroslavsky, Jason, Kuan, J C, Kraemer, L, Arcebuche, L, Hernandez, L, Hart, Meghan, Kounlavouth, Sonia, Garbes, Pedro, Allen, A, Jooss, Karin, Mahdi, Shabhir A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678953/ http://dx.doi.org/10.1093/ofid/ofad500.1993 |
Ejemplares similares
-
2346. Preliminary results of durable immune response induced by a self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidate, GRT-R910, in adults previously vaccinated with mRNA or AZD1222 primary series
por: Uriel, Alison, et al.
Publicado: (2023) -
2395. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults
por: Whitaker, Jennifer, et al.
Publicado: (2023) -
GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
por: Palmer, Christine D., et al.
Publicado: (2023) -
2372. PCR Ribotype and Antimicrobial Susceptibility of Clostridioides (Formerly Clostridium) difficile in Korea
por: Hoo Jeon, Cheon, et al.
Publicado: (2019) -
2372: Metabolite and biomarker predictors of WTC-lung injury: An integrated multiplatform pilot analysis
por: Crowley, George, et al.
Publicado: (2018)